Hagop Kantarjian, MD of MD Anderson Cancer Center discusses the new targetable molecular abnormalities in AML at the Scripps 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content